Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
The chart shows the growth of an initial investment of $10,000 in Veeva Systems Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Veeva Systems Inc. (VEEV) has returned -22.13% so far this year and -15.22% over the past 12 months. Looking at the last ten years, VEEV has achieved an annualized return of 21.39%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Veeva Systems Inc. (VEEV) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.72% | -10.30% | -2.49% | -1.53% | ||||||||
| 2025 | 9.75% | -2.55% | 3.26% | 2.51% | 19.02% | 4.22% | -1.17% | -3.86% | 12.31% | -1.10% | -17.43% | -5.92% |
| 2024 | 8.50% | 10.70% | 4.72% | -14.09% | -12.28% | 3.94% | 4.90% | 12.62% | -2.75% | -0.61% | 8.70% | -7.63% |
| 2023 | 4.23% | -3.22% | 10.15% | -1.64% | -7.17% | 4.62% | 3.63% | 3.01% | -3.41% | -4.63% | -9.21% | 10.62% |
| 2022 | -7.74% | -3.01% | -6.35% | -14.01% | -5.91% | 14.28% | 11.89% | -10.55% | -5.65% | 2.40% | 11.30% | -15.53% |
| 2021 | 0.89% | 1.17% | -9.27% | 6.37% | 2.74% | 8.07% | 7.33% | -0.52% | -13.61% | 9.86% | -10.89% | -10.81% |
| 2020 | 3.25% | -3.76% | 9.90% | 26.91% | 15.55% | 8.19% | 12.58% | 5.40% | -1.55% | -4.79% | 2.20% | -2.67% |
| 2019 | 24.57% | 8.17% | 6.74% | 9.27% | 9.33% | 4.68% | 0.17% | -3.11% | -4.38% | -7.00% | 4.68% | -5.35% |
| 2018 | 13.63% | 11.40% | 5.02% | -3.52% | 11.05% | -1.46% | -0.51% | 37.90% | 4.47% | -15.02% | 4.93% | -9.93% |
| 2017 | 3.22% | 3.02% | 19.09% | 4.52% | 17.69% | -3.99% | 3.56% | -7.03% | -5.65% | 8.01% | -1.99% | -7.94% |
| 2016 | 10.70% | 19.64% | 3.71% | 11.51% | 6.53% | -0.19% | -6.34% | 19.95% | -12.44% |
The charts below present risk-adjusted performance metrics for Veeva Systems Inc. (VEEV) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of VEEV compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Veeva Systems Inc. volatility is 1.98%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 8.98B | 7.34B | 5.91B | 4.80B | 3.82B | 3.05B | 2.27B | 1.65B | 1.20B | 917.70M | 705.80M | 544.89M | 370.31M |
| Equity Attributable To Parent (USD) | 7.21B | 5.83B | 4.64B | 3.72B | 2.91B | 2.27B | 1.67B | 1.24B | 871.53M | 652.98M | 505.25M | 406.83M | 280.10M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 7.21B | 5.83B | 4.64B | 3.72B | 2.91B | 2.27B | 1.67B | 1.24B | 871.53M | 652.98M | 505.25M | 406.83M | 280.10M |
| Noncurrent Liabilities (USD) | 127.54M | 108.98M | 87.21M | 81.24M | 64.05M | 63.80M | 55.01M | 15.00M | 10.81M | 17.94M | 14.27M | 2.53M | 3.60M |
| Other Current Liabilities (USD) | 1.55B | 1.33B | 1.10B | 920.84M | 786.60M | 662.29M | 506.13M | 376.59M | 290.68M | 229.10M | 169.23M | 125.14M | 84.50M |
| Wages (USD) | 45.86M | 39.43M | 43.43M | 44.28M | 33.83M | 30.41M | 25.62M | 15.32M | 17.05M | 12.01M | 12.45M | 6.50M | - |
| Accounts Payable (USD) | 37.64M | 30.45M | 31.51M | 41.68M | 20.35M | 23.25M | 19.42M | 9.11M | 6.94M | 5.68M | 4.60M | 3.89M | 2.12M |
| Current Liabilities (USD) | 1.64B | 1.40B | 1.18B | 1.01B | 840.78M | 715.95M | 551.17M | 401.02M | 314.68M | 246.78M | 186.28M | 135.52M | 86.62M |
| Liabilities (USD) | 1.76B | 1.51B | 1.27B | 1.09B | 904.83M | 779.75M | 606.18M | 416.02M | 325.48M | 264.72M | 200.55M | 138.06M | 90.21M |
| Other Non-current Assets (USD) | 911.45M | 975.04M | 849.18M | 785.17M | 654.79M | 681.59M | 685.90M | 165.39M | 136.59M | 155.93M | 157.37M | 14.85M | 14.13M |
| Fixed Assets (USD) | 70.26M | 55.91M | 58.53M | 49.82M | 54.50M | 53.65M | 54.75M | 54.97M | 52.28M | 49.91M | 47.47M | 28.20M | 2.45M |
| Noncurrent Assets (USD) | 981.71M | 1.03B | 907.71M | 834.98M | 709.28M | 735.24M | 740.65M | 220.35M | 188.87M | 205.84M | 204.84M | 43.05M | 16.58M |
| Current Assets (USD) | 8.00B | 6.31B | 5.00B | 3.97B | 3.11B | 2.31B | 1.53B | 1.43B | 1.01B | 711.87M | 500.96M | 501.84M | 353.73M |
| Assets (USD) | 8.98B | 7.34B | 5.91B | 4.80B | 3.82B | 3.05B | 2.27B | 1.65B | 1.20B | 917.70M | 705.80M | 544.89M | 370.31M |
Veeva Systems, a cloud software leader for life sciences companies, has declined 37% over six months due to competition concerns. However, the article argues the stock is now attractive due to its strong market position, AI investments, large addressable market ($20B+), and valuation at forward P/E of ~20, suggesting potential for strong returns over the next five years.
Veeva Systems has delivered solid 13.6% CAGR returns since its 2013 IPO and could help investors build multimillion-dollar portfolios over 30 years. The cloud specialist serves the life sciences industry with strong competitive advantages, including high switching costs and leadership among top biopharma companies. Despite facing increased competition and slowing revenue growth, Veeva's large addressable market ($20B) and expansion into new sectors position it well for long-term growth.
U.S. stock futures declined on Thursday following geopolitical tensions in the Middle East, with reports of Iran initiating contact with Trump for ceasefire negotiations. The S&P 500 and Nasdaq 100 fell slightly in premarket trading. Notable movers included Broadcom surging 6.66% on better-than-expected Q1 results, Veeva Systems rising 11.32% on strong guidance, Trade Desk jumping 16.85% following insider buying, and Webull falling 3.13% after missing profit targets.
The article recommends two growth stocks for long-term investors: Eli Lilly, a pharmaceutical leader in anti-obesity medicines with strong double-digit growth and AI-powered drug development initiatives, and Veeva Systems, a cloud solutions provider for life science companies with a $20 billion addressable market and a goal to double revenue by 2030.
The global pharmacovigilance market is projected to grow from USD 8.91 billion in 2025 to USD 24.69 billion by 2035, at a CAGR of 10.34%. Growth is driven by stringent regulatory requirements, increased adverse drug reaction incidents, and pharmaceutical industry expansion into emerging markets. The U.S. market alone is expected to reach USD 9.48 billion by 2035. Phase IV post-market surveillance and contract outsourcing services dominate the market segments.
Despite a 35% stock decline over the past six months due to competition concerns, Veeva Systems remains a solid long-term buy. The company's specialized cloud services for life sciences companies create strong switching costs and competitive advantages. With a goal to double revenue to $6 billion by 2030 and a history of meeting targets, Veeva is well-positioned to capitalize on the expanding life sciences industry.
The global clinical trials support software solutions market is valued at USD 14.31 billion in 2026 and is expected to reach USD 34.15 billion by 2035, growing at a 10.15% CAGR. North America leads the market while Asia Pacific shows the fastest growth. CTMS solutions dominate by product type, cloud-based delivery leads, and CROs lead by end-user segment. Key growth drivers include increasing clinical trial complexity, adoption of decentralized trials, AI-driven analytics, and regulatory compliance demands.
Three software stocks—Okta, Veeva Systems, and Guidewire Software—have announced significant share buyback programs following substantial declines in their stock prices. Okta authorized a $1 billion buyback after falling 28% from its 52-week high, Veeva announced its first-ever $2 billion program after dropping 21%, and Guidewire launched a $500 million buyback following a 29% decline. These announcements signal management confidence that their shares are undervalued, with analysts seeing the most upside potential in Guidewire.
The Electronic Clinical Outcome Assessment (eCOA) Solutions Market is expected to grow from USD 1.57 billion in 2023 to USD 5.64 billion by 2032, with a 15.3% CAGR, driven by digital transformation in clinical research and increasing regulatory compliance requirements.
The article highlights Netflix and Veeva Systems as promising growth stocks for investors, discussing their market positions, recent performance, and potential for future expansion in streaming and cloud computing sectors.
